Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2014-10-10 Major Shareholding Noti…
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2014
Major Shareholding Notification
2014-10-10 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(5) related to a public offering of units consisting of common stock and warrants by Titan Pharmaceuticals, Inc. It includes extensive information about the offering terms, risk factors, use of proceeds, underwriting arrangements, and company business overview. This type of document is a registration statement prospectus used for capital raising and financing activities. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but the full prospectus filing.
2014-10-03 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content describes the pricing of a public offering of units and adjustments to warrant exercise prices due to anti-dilution provisions. There is no detailed financial statement or comprehensive financial analysis, but rather an announcement of a financing event. The document length is short (2575 characters), and it includes a press release as an exhibit. This fits the category of a Capital/Financing Update, as it relates to fundraising and capital structure changes.
2014-10-03 English
Regulatory Filings 2014
Regulatory Filings
2014-10-03 English
S-1MEF
Regulatory Filings Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement for securities offering, including details about the registrant, securities being registered, and legal consents. It is not a financial report like an Annual Report or Interim Report, nor is it a transcript, proxy, or voting result. The document is a regulatory filing related to capital raising but is not an update or announcement of financing activity per se. Given the nature of Form S-1 filings, which are registration statements for securities offerings, the best fitting category is Regulatory Filings (RNS), as it does not fit the more specific Capital/Financing Update (CAP) which typically covers updates on financing activities after the offering is underway. The document is also not a report publication announcement since it is the filing itself. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2014-10-02 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC, dated September 30, 2014. It is a registration statement under the Securities Act of 1933 for Titan Pharmaceuticals, Inc. The text includes detailed information about the securities being registered, offering terms, underwriting arrangements, risk factors, and other disclosures typical of a registration statement for an initial public offering or other securities offering. This is not an annual report, earnings release, or any other financial report. It is a capital raising filing related to the registration of securities for sale to the public. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2014-09-30 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.